Cargando…

Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma

INTRODUCTION: p21-activated kinase 1 (PAK1) stimulates growth and metastasis in non-small cell lung cancer (NSCLC). Protein kinase C iota (PKCι) is an enzyme highly expressed in NSCLC, regulating PAK1 signaling. In the present study we explored whether the PKCι-PAK1 signaling pathway approach can be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ito, Masaoki, Codony-Servat, Carles, Codony-Servat, Jordi, Lligé, David, Chaib, Imane, Sun, Xiaoyan, Miao, Jing, Sun, Rongwei, Cai, Xueting, Verlicchi, Alberto, Okada, Morihito, Molina-Vila, Miguel Angel, Karachaliou, Niki, Cao, Peng, Rosell, Rafael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819333/ https://www.ncbi.nlm.nih.gov/pubmed/31660987 http://dx.doi.org/10.1186/s12964-019-0446-z

Ejemplares similares

STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer
por: Attili, Ilaria, et al.
Publicado: (2018)

Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC)
por: Codony-Servat, Carles, et al.
Publicado: (2017)

Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)
por: Bracht, Jillian Wilhelmina Paulina, et al.
Publicado: (2019)

Src-Homology 2 Domain-Containing Phosphatase 2 in Resected EGFR Mutation-Positive Lung Adenocarcinoma
por: Ito, Masaoki, et al.
Publicado: (2020)

Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC)
por: Karachaliou, Niki, et al.
Publicado: (2018)

SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer
por: Attili, Ilaria, et al.
Publicado: (2020)

Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-Small Cell Lung Cancer Associated With Poor Prognosis
por: Karachaliou, Niki, et al.
Publicado: (2018)

Acquired BRAF gene fusions in Osimertinib resistant EGFR-mutant non-small cell lung cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy
por: Bertran-Alamillo, Jordi, et al.
Publicado: (2019)

Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities
por: Rosell, Rafael, et al.
Publicado: (2021)

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC
por: Chaib, Imane, et al.
Publicado: (2017)

Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
por: Jacobsen, Kirstine, et al.
Publicado: (2017)

Carbodiimide-mediated cross-linking of RNA to nylon membranes improves the detection of siRNA, miRNA and piRNA by northern blot
por: Pall, Gurman Singh, et al.
Publicado: (2007)

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
por: Karachaliou, Niki, et al.
Publicado: (2015)

Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
por: Karachaliou, Niki, et al.
Publicado: (2023)

Anti-epidermal growth factor vaccine antibodies increase the antitumor activity of kinase inhibitors in ALK and RET rearranged lung cancer cells
por: Codony-Servat, Jordi, et al.
Publicado: (2020)

Biological insights in non-small cell lung cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

Coordination of glioblastoma cell motility by PKCι
por: Baldwin, R Mitchell, et al.
Publicado: (2010)

Oncogenic PKC-ι activates Vimentin during epithelial-mesenchymal transition in melanoma; a study based on PKC-ι and PKC-ζ specific inhibitors
por: Ratnayake, Wishrawana S., et al.
Publicado: (2018)

Commentary: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer
por: Rosell, Rafael, et al.
Publicado: (2020)

A narrative review of the migration and invasion features of non-small cell lung cancer cells upon xenobiotic exposure: insights from in vitro studies
por: Albuquerque, Catarina, et al.
Publicado: (2021)

PKCι and YAP1 are crucial in promoting pancreatic tumorigenesis
por: Wang, Peipei, et al.
Publicado: (2018)

PKCι depletion initiates mitotic slippage-induced senescence in glioblastoma
por: Restall, Ian J, et al.
Publicado: (2015)

Investigating pathogenic SNP of PKCι in HCV-induced hepatocellular carcinoma
por: Khan, Naila, et al.
Publicado: (2023)

PKCι regulates nuclear YAP1 localization and ovarian cancer tumorigenesis
por: Wang, Yin, et al.
Publicado: (2016)

Deciphering Crosstalk Circuits in Non-small Cell Lung Cancers with an Increasing Interval Length of Low Dose CT Screening
por: Rosell, Rafael, et al.
Publicado: (2015)

The aPKCι blocking agent ATM negatively regulates EMT and invasion of hepatocellular carcinoma
por: Ma, C Q, et al.
Publicado: (2014)

Lack of an association between the aPKCλ/ι expression in prostate cancer and the patient outcomes
por: Yokomizo, Yumiko, et al.
Publicado: (2017)

PKCλ/ι signaling—a common node for normal cellular development and breast oncogenesis
por: Paul, Arindam, et al.
Publicado: (2015)

Clinical significance of atypical protein kinase C (PKCι and PKCζ) and its relationship with yes-associated protein in lung adenocarcinoma
por: Kim, Kyung-Hee, et al.
Publicado: (2019)

Distribution and prognostic impact of EGFR and KRAS mutations according to histological subtype and tumor invasion status in pTis-3N0M0 lung adenocarcinoma
por: Ito, Masaoki, et al.
Publicado: (2023)

Activation of nuclear factor-κB in human prostate carcinogenesis and association to biochemical relapse
por: Domingo-Domenech, J, et al.
Publicado: (2005)

Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies
por: Santarpia, Mariacarmela, et al.
Publicado: (2020)

BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib
por: Karachaliou, Niki, et al.
Publicado: (2020)

Commentary: Reducing Viability Bias in Analysis of Gut Microbiota in Preterm Infants at Risk of NEC and Sepsis
por: Agustí, Gemma, et al.
Publicado: (2018)

Ect2 links the PKCι-Par6α Complex to Rac1 Activation and Cellular Transformation
por: Justilien, Verline, et al.
Publicado: (2009)

PKCι interacts with Rab14 and modulates epithelial barrier function through regulation of claudin-2 levels
por: Lu, Ruifeng, et al.
Publicado: (2015)

The Rho family GEF FARP2 is activated by aPKCι to control tight junction formation and polarity
por: Elbediwy, Ahmed, et al.
Publicado: (2019)

Hypoxia-induced therapy resistance: Available hypoxia-targeting strategies and current advances in head and neck cancer
por: Codony, Victoria L., et al.
Publicado: (2021)

Conditional knockout of polarity complex (atypical) PKCι reveals an anti-inflammatory function mediated by NF-κB
por: Forteza, Radia, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_qd74m5eph4vaf4uujdef5rf50q